1. Innate and adaptive immune responses following PD‐L1 blockade in treating chronic murine alveolar echinococcosis
- Author
-
Bruno Gottstein, Anne-Pauline Bellanger, Junhua Wang, Christine Goepfert, Michel Dosch, Laurence Millon, Britta Lunström-Stadelmann, Fadi Jebbawi, Denis Grandgirard, Guido Beldi, Stephen L. Leib, Reto Rufener, Department of Visceral and Transplant Surgery, University Hospital Berne, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de parasitologie et mycologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland, and Institute for Infectious Diseases, Faculty of Medicine, University of Berne, 3001 Berne, Switzerland
- Subjects
0301 basic medicine ,anti-PD-L1 ,medicine.medical_treatment ,T cell ,Programmed Cell Death 1 Receptor ,030231 tropical medicine ,Immunology ,albendazole ,610 Medicine & health ,CD8-Positive T-Lymphocytes ,B7-H1 Antigen ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Echinococcosis ,PD-L1 ,medicine ,Animals ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,Innate immune system ,630 Agriculture ,biology ,Immunity ,Immunotherapy ,Immune checkpoint ,3. Good health ,Blockade ,030104 developmental biology ,Cytokine ,medicine.anatomical_structure ,biology.protein ,570 Life sciences ,Echinococcus multilocularis ,Parasitology ,immunotherapy - Abstract
BACKGROUND Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) immune checkpoint blockade is efficacious in certain cancer therapies. OBJECTIVES The present study aimed to provide a picture about the development of innate and adaptive immune responses upon PD-L1 blockade in treating chronic murine AE. METHODS Immune treatment started at 6 weeks post E. multilocularis-infection, and was maintained for 8 weeks with twice per week anti-PD-L1 administration (intraperitoneal). The study included an outgroup-control with mice perorally medicated with albendazole five days/week, and another one with both treatments combined. Assessment of treatment efficacy was based on determining parasite weight, innate and adaptive immune cell profiles, histopathology, and liver tissue cytokine levels. RESULTS/CONCLUSIONS Findings showed that the parasite load was significantly reduced in response to PD-L1 blockade, and this blockade a) contributed to T cell activity by increasing CD4+ /CD8+ effector T cells, and decreasing Tregs; b) had the capacity to re-store DCs and Kupffer cells/Macrophages; c) suppressed NKT and NK cells; and thus d) lead to an improved control of E. multilocularis infection in mice. This study suggests that the PD-L1 pathway plays an important role by regulating adaptive and innate immune cells against E. multilocularis infection, with significant modulation of tissue inflammation.
- Published
- 2021
- Full Text
- View/download PDF